Outlook Therapeutics
OTLK
11 hedge funds and large institutions have $4.31M invested in Outlook Therapeutics in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
30% more capital invested
Capital invested by funds: $3.32M → $4.31M (+$996K)
0.01% more ownership
Funds ownership: 0.09% → 0.1% (+0.01%)
27% less funds holding
Funds holding: 15 → 11 (-4)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.46M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$2.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$123K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$30K |
| 3 |
BlackRock
New York
|
-$27K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.39K |
| 5 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $3.12M | +$1.46M | +9,903 | +75% |
|
|
ACA
2
Avoro Capital Advisors
New York
| $578K | – | – | – |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $261K | -$3.39K | -23 | -1% |
|
|
MWNA
4
Marshall Wace North America
New York
| $220K | – | – | – |
|
|
PAM
5
Panagora Asset Management
Boston,
Massachusetts
| $51K | +$2.8K | +19 | +5% |
|
|
ACP
6
Acuta Capital Partners
Redwood City,
California
| $25K | – | – | – |
|
|
TSS
7
Two Sigma Securities
New York
| $19K | -$147 | -1 | -0.7% |
|
8
Morgan Stanley
New York
| $14K | – | – | – |
|
9
Geode Capital Management
Boston,
Massachusetts
| $9K | – | – | – |
|
10
UBS Group
Zurich,
Switzerland
| $8K | -$1.47K | -10 | -14% |
|
11
Bank of America
Charlotte,
North Carolina
| $8K | – | – | – |
|
|
BCM
12
Bridgeway Capital Management
Houston,
Texas
| – | -$123K | -863 | Closed |
|
|
13
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$30K | -211 | Closed |
|
|
14
BlackRock
New York
| – | -$27K | -194 | Closed |
|
|
ASN
15
Advisory Services Network
Atlanta,
Georgia
| – | -$2K | -13 | Closed |
|
OTLK Hedge Fund Activity: Q2 2018 in Review
11 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2018, worth a combined $4.31M — up 30% from $3.32M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of OTLK and 0 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Sabby Management, adding an estimated $1.46M. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $123K sold.
- 11 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2018, down from 15 in Q1 2018.
- Funds reported $4.31M of Outlook Therapeutics stock for Q2 2018, up 30% quarter-over-quarter.
- 0 funds opened new Outlook Therapeutics positions in Q2 2018 and 4 closed out, a net change of -4 holders.
- The largest Outlook Therapeutics buyer in Q2 2018 was Sabby Management, an estimated $1.46M added.
- The largest Outlook Therapeutics seller in Q2 2018 was Bridgeway Capital Management, an estimated $123K sold.
Based on aggregated 13F filings for Q2 2018.